|
| Product Name: | SKI II | | Synonyms: | SKIII(SphK-I2), >98%;SKI II - SKI 2;SPHINGOSINE KINASE INHIBITOR;SPHINGOSINE KINASE INHIBITOR 2;SKI II (SPHK-I2);SPHK-I2;SKI II (SPHINGOSINE KINASE INHIBITOR);CS-1145;Sphingosine Kinase Inhibitor;Sphingosine Kinase Inhibitor 2;SKI II (SphK-I2);SphK-I2 | | CAS: | 312636-16-1 | | MF: | C15H11ClN2OS | | MW: | 302.78 | | EINECS: | | | Product Categories: | Inhibitors;Lysophospholipid receptor and related | | Mol File: | 312636-16-1.mol |  |
| | SKI II Chemical Properties |
| Boiling point | 507.1±60.0 °C(Predicted) | | density | 1.415±0.06 g/cm3(Predicted) | | RTECS | SK5900000 | | storage temp. | 2-8°C | | solubility | DMSO: ≥20 mg/mL | | form | solid | | pka | 10.17±0.26(Predicted) | | color | off-white | | Sensitive | Air & Light Sensitive | | CAS DataBase Reference | 312636-16-1 |
| | SKI II Usage And Synthesis |
| Uses | SKI II is a nonlipid inhibitor of sphingosine kinase. SKI II s orally bioavailable and has shown significant inhibition of tumor growth in mice. | | Definition | ChEBI: 4-[[4-(4-chlorophenyl)-2-thiazolyl]amino]phenol is a substituted aniline. | | Biological Activity | Selective non-lipid inhibitor of sphingosine kinase (IC 50 = 0.5 μ M); does not act at ATP-binding site. Displays no inhibition of ERK2, PI 3-kinase, or PKC α at concentrations up to 60 μ M. Reduces levels of sphingosine-1-phosphate in MDA-MB-231 breast cancer cells. Induces apoptosis and inhibits proliferation in several other tumor cell lines in vitro (IC 50 = 0.9-4.6 μ M). | | Biochem/physiol Actions | Sphingosine kinase (SK) plays a pivotal role in regulating tumor growth and SK can act as an oncogene. Expression of SK RNA is significantly elevated in a variety of solid tumors, compared with normal tissue from the same patient. A number of novel inhibitors of human SK were identified, and several representative compounds were characterized in detail. These compounds demonstrated activity at sub- to micromolar concentrations, making them more potent than any other reported SK inhibitor, and were selective toward SK compared with a panel of human lipid and protein kinases. Kinetic studies revealed that the compounds were not competitive inhibitors of the ATP-binding site of SK. 4-[4-(4-chloro-phenyl)-thiazol-2-ylamino]-phenol (SKI-II) inhibitor is orally bioavailable, detected in the blood for at least 8 h, and showed a significant inhibition of tumor growth in mice with IC50 = 0.5 μM; SKI II does not act at ATP-binding site. Displays no inhibition of ERK2, PI 3-kinase, or PKCa at concentrations up to 60 μM.SKI II induces apoptosis and inhibits proliferation in several other tumor cell lines in vitro (IC50 = 0.9-4.6 μM). | | storage | Store at -20°C | | references | [1] french kj, schrecengost rs, lee bd, zhuang y, smith sn, eberly jl, yun jk, smith cd. discovery and evaluation of inhibitors of human sphingosine kinase. cancer res. 2003 sep 15;63(18):5962-9. |
| | SKI II Preparation Products And Raw materials |
|
